VCYT Veracyte Inc
Price (delayed)
$28.57
Market cap
$2.19B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.74
Enterprise value
$1.98B
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other
Highlights
Veracyte's gross profit has increased by 28% YoY and by 9% QoQ
Veracyte's revenue has increased by 22% YoY and by 6% QoQ
Veracyte's net income has shrunk by 86% YoY but it has increased by 21% QoQ
The EPS has dropped by 85% year-on-year but it has increased by 20% since the previous quarter
The debt has grown by 48% from the previous quarter and by 40% YoY
The company's quick ratio fell by 10% QoQ
Key stats
What are the main financial stats of VCYT
Market
Valuations
Earnings
Shares outstanding
76.81M
Market cap
$2.19B
Enterprise value
$1.98B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.93
Price to sales (P/S)
5.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.95
Revenue
$399.58M
EBIT
-$54.79M
EBITDA
-$25.34M
Free cash flow
$40.13M
Per share
Balance sheet
Liquidity
EPS
-$0.74
Free cash flow per share
$0.52
Book value per share
$14.81
Revenue per share
$5.22
TBVPS
$4.83
Total assets
$1.23B
Total liabilities
$101.8M
Debt
$20.74M
Equity
$1.13B
Working capital
$248.77M
Debt to equity
0.02
Current ratio
4.44
Quick ratio
3.97
Net debt/EBITDA
8.54
Margins
Efficiency
Dividend
EBITDA margin
-6.3%
Gross margin
68.7%
Net margin
-13.5%
Operating margin
-16.8%
Return on assets
-4.6%
Return on equity
-5%
Return on invested capital
-79.6%
Return on capital employed
-4.7%
Return on sales
-13.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCYT stock price
How has the Veracyte stock price performed over time
Intraday
-4.03%
1 week
-9.45%
1 month
30.93%
1 year
9.84%
YTD
3.85%
QTD
31.84%
Financial performance
How have Veracyte's revenue and profit performed over time
Revenue
$399.58M
Gross profit
$274.62M
Operating income
-$67.3M
Net income
-$54.04M
Gross margin
68.7%
Net margin
-13.5%
The operating income has plunged by 100% YoY but it has grown by 16% from the previous quarter
Veracyte's net income has shrunk by 86% YoY but it has increased by 21% QoQ
The operating margin has plunged by 65% YoY but it has grown by 21% from the previous quarter
The net margin has plunged by 53% YoY but it has grown by 26% from the previous quarter
Growth
What is Veracyte's growth rate over time
Valuation
What is Veracyte stock price valuation
P/E
N/A
P/B
1.93
P/S
5.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.95
The EPS has dropped by 85% year-on-year but it has increased by 20% since the previous quarter
The P/B is 36% below the 5-year quarterly average of 3.0 but 21% above the last 4 quarters average of 1.6
The equity has grown by 4.6% YoY
The P/S is 47% below the 5-year quarterly average of 10.4 but 16% above the last 4 quarters average of 4.7
Veracyte's revenue has increased by 22% YoY and by 6% QoQ
Efficiency
How efficient is Veracyte business performance
VCYT's return on invested capital has dropped by 88% year-on-year but it is up by 28% since the previous quarter
The company's return on equity has shrunk by 85% YoY but it rose by 21% QoQ
The ROA has plunged by 84% YoY but it has grown by 22% from the previous quarter
The return on sales has dropped by 57% year-on-year but it has increased by 27% since the previous quarter
Dividends
What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCYT.
Financial health
How did Veracyte financials performed over time
The total liabilities has grown by 30% YoY and by 25% from the previous quarter
The company's current ratio fell by 11% QoQ
The debt is 98% less than the equity
VCYT's debt to equity has surged by 100% since the previous quarter and by 100% year-on-year
The debt has grown by 48% from the previous quarter and by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.